John P. Dubinsky

This profile gathers the share dealings of John P. Dubinsky across 3 companies, led by Stifel Financial Corp, Aegion Corp and Accentia Biopharmaceuticals Inc. In total, 58 filings cover trades dated from 3 April 2006 to 3 June 2020.

The open-market side counts 4 purchases for €173k alongside 22 sales for €2.7M. Netting one side against the other leaves €2.5M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 8 share grants and 22 option exercises. Since January 2020: no purchases and 4 sales on the market.

Half of the purchases are above €34k and half below.

The newest entry dates from 4 June 2020: an open-market sale of €110k, in Stifel Financial Corp. The latest purchase dates back some time: it was published 7,307 days ago, on 6 November 2006. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.